Zydus Lifesciences

Zydus Lifesciences

ZYDUSLIFE

 ₹ 900.42
- ₹ 1.84
0.20%
Healthcare
 ₹ 0.00
(%)1D
Updated: 26 Mar 2025, 03:31:03 pm IST
Stock Score
Open Price
 ₹ 903.66
Prev. Close
 ₹ 902.26
 ₹ 896.49
Day Low
 ₹ 910.49
Day High

 ₹ 845.81
52 Week Low
 ₹ 1,445.31
52 Week High

Quick Bite

Price To Earnings Ratio

23.47

Sector PE

64.22

PB Ratio

4.57

Sector PB

8.24

EPS

38.36

Dividend Yield

0.30

Today's Volume

1.468 M

5 Day Avg. Volume

1.109 M

PEG Ratio

0.24

Market Cap.

₹ 92,430.00 Cr.

News & Events

About Zydus Lifesciences

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Zydus Lifesciences Share Price

Zydus Lifesciences Ltd. is an Indian life sciences company. The Company is engaged in the research and development, manufacturing, marketing and sale of human medicines, such as generic medicines and specialty products, including biosimilars and vaccines; active pharmaceutical ingredients (API); animal health products and consumer protection products. Its products include Bilypsa (saroglitisar), Oxemia (desidustat), Ujvira (biologically similar to Kadcyla), and Exemptia. It offers Bilypsa for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule, hypoxia-inducible factor-prolyl-hydroxylase (HIF-PH) inhibitor used to treat anemia in patients with chronic kidney disease (CKD). He is also developing an oral ZYIL1 small molecule to selectively suppress inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine against COVID-19.

Zydus Lifesciences FAQs

How to Buy Zydus Lifesciences Share?

up
To purchase Zydus Lifesciences shares, you can open a Demat & Trading account through a broker or financial institution. Once your account is set up and funded, search for Zydus Lifesciences (ticker symbol: ZYDUSLIFE) on the trading platform provided by your broker and purchase the shares.

What's Zydus Lifesciences share price today?

up
The stock price of Zydus Lifesciences as of 02 Apr 2025 is ₹900.42

What is the Market Cap of Zydus Lifesciences?

up
Market capitalisation represents the total market value of a company's outstanding shares. As of 02 Apr 2025, Zydus Lifesciences (ticker symbol: ZYDUSLIFE) has a market capitalisation of approximately ₹9,24,30,00,00,000.00

What is the PE and PB ratio of Zydus Lifesciences?

up
Zydus Lifesciences Ltd's price-to-book ratio as of 02 Apr 2025 is 4.57, reflecting the market's valuation compared to its asset value. As of 02 Apr 2025, the trailing twelve months P/E (price-to-earnings) ratio is 23.47, indicating the market values the company at around ₹23.47 for every ₹1 of earnings

What is the 52 Week High and Low of Zydus Lifesciences Share?

up
Zydus Lifesciences Ltd (ZYDUSLIFE) hit its 52-week high at ₹1,445.31, and its 52-week low at ₹845.81.
Begin your investment journey today
Login/Register
Start Now